Bavarian Nordic injects debt for GSK vaccines
Denmark’s Bavarian Nordic will buy two commercial vaccines from GlaxoSmithKline for €796m, in a debt funded acquisition that will be refinanced next year in the equity market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: